KR920016454A - 환-치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만 - Google Patents

환-치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만 Download PDF

Info

Publication number
KR920016454A
KR920016454A KR1019920001720A KR920001720A KR920016454A KR 920016454 A KR920016454 A KR 920016454A KR 1019920001720 A KR1019920001720 A KR 1019920001720A KR 920001720 A KR920001720 A KR 920001720A KR 920016454 A KR920016454 A KR 920016454A
Authority
KR
South Korea
Prior art keywords
alkyl
tetrahydronaphthalene
aryl
pharmaceutically acceptable
cyclopropylmethyl
Prior art date
Application number
KR1019920001720A
Other languages
English (en)
Other versions
KR100219995B1 (ko
Inventor
스티븐 훽스테터 크레이그
린 휴저 다이안
메너트 샤우스 죤
다니엘 티투스 로버트
Original Assignee
원본미기재
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 일라이 릴리 앤드 캄파니 filed Critical 원본미기재
Publication of KR920016454A publication Critical patent/KR920016454A/ko
Application granted granted Critical
Publication of KR100219995B1 publication Critical patent/KR100219995B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyrane Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

환-치환된2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기 일반식(I)의 화합물 및 약학적으로 허용가능한 그의 산 부가염 및 용매화물:
    상기식에서, R은 C1-C4알킬, 아릴 또는 사이클로프로필메틸이고, R1은 수소,C1-C4-알킬, 아릴, 사이클로프로필메틸 또는 아릴(C1-C4-알킬)이며, X는-CH2-또는 -O-이고, Y는 그것이 결합되는 탄소원자와 함께및중에서 선택된 치환되거나 또는 치환되지 않은 방향족 헤테로고리 5원환이며, Ra는 각각 독립적으로 수소, C1-C4-알킬, C1-C4-알콕시, C1-C4-알킬티오, 하이드록시, 아미노, 시아노, 또는 페닐이다.
  2. 제1항에 있어서, 2-디-n-프로필아미노-8-(이속사졸-5-일)-1,2,3,4-테트라하이드로나프탈렌인 화합물.
  3. 제1항에 있어서, 2-디-n-프로필아미노-8-(이속사졸-3-일)-1,2,3,4-테트라하이드로나프탈렌인 화합물.
  4. 활성성분으로서의 제1항 내지 제3항중 어느 한 항에 따른 화합물, 또는 약학적으로 허용가능한 그의 염 또는 용매화물과 함께 하나이상의 약학적으로 허용가능한 담체, 부형제 또는 희석제를 포함하는 5-HT1A작용물질 활성을 갖는 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920001720A 1991-02-08 1992-02-06 환-치환된2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만 KR100219995B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65358391A 1991-02-08 1991-02-08
US7/653,583 1991-02-08
US07/653,583 1991-02-08

Publications (2)

Publication Number Publication Date
KR920016454A true KR920016454A (ko) 1992-09-24
KR100219995B1 KR100219995B1 (ko) 1999-09-01

Family

ID=24621480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920001720A KR100219995B1 (ko) 1991-02-08 1992-02-06 환-치환된2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만

Country Status (26)

Country Link
US (2) US5426226A (ko)
EP (2) EP0712837B1 (ko)
JP (1) JP3283892B2 (ko)
KR (1) KR100219995B1 (ko)
CN (2) CN1036392C (ko)
AT (2) ATE197145T1 (ko)
AU (2) AU653197B2 (ko)
BR (1) BR9200426A (ko)
CA (1) CA2060815C (ko)
CZ (1) CZ288067B6 (ko)
DE (2) DE69218813T2 (ko)
DK (2) DK0498590T3 (ko)
ES (2) ES2102456T3 (ko)
FI (1) FI920526A (ko)
GR (2) GR3023601T3 (ko)
HU (3) HU225163B1 (ko)
IE (1) IE920417A1 (ko)
IL (3) IL114760A (ko)
MX (1) MX9200505A (ko)
MY (1) MY116454A (ko)
NO (1) NO301825B1 (ko)
NZ (2) NZ241495A (ko)
PT (1) PT712837E (ko)
RU (2) RU2057751C1 (ko)
YU (1) YU48927B (ko)
ZA (1) ZA92767B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124868T2 (de) * 1990-08-15 1997-07-10 Lilly Co Eli Ring-substituierte 2-Amino-1,2,3,4-tetra-hydronaphthaline, 3-Aminochromane und 3-Aminothiochromane
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
EP0697894A4 (en) * 1993-03-31 1996-05-01 Univ Pennsylvania DOPAMINE D-3 AND SEROTONIN (5-HT 1A) RECEPTOR LIGANDS AND IMAGING AGENTS
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO1998048786A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company AMINOTETRALINS AS 5-HT1Dα AGONISTS
US6355674B1 (en) 1997-04-30 2002-03-12 Eli Lilly And Company Aminotetralins as 5-HT1D α Agonists
WO1999001121A1 (en) 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6573218B1 (en) 1998-09-09 2003-06-03 Ishihara Sangyo Kaisha, Ltd. Fused-benzene derivatives useful as herbicides
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6792563B1 (en) * 2000-04-28 2004-09-14 Intel Corporation Method and apparatus for bus activity tracking
JP2005526720A (ja) * 2002-02-13 2005-09-08 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192641A (en) * 1979-01-26 1984-10-19 Hoffmann La Roche Substituted acetophenones and pharmaceutical compositions
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
FR2647365B1 (fr) * 1989-05-24 1991-08-30 Inst Francais Du Petrole Catalyseur multifonctionnel pour le traitement des gaz d'echappement des moteurs a combustion interne, contenant de l'uranium, au moins un promoteur de l'uranium et au moins un metal precieux et sa preparation
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
DE3919624A1 (de) * 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU631017B2 (en) * 1989-10-23 1992-11-12 Sumitomo Chemical Company, Limited 5-substituted-2,4-diphenylpyrimidine derivatives, their production and use
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
DE69124868T2 (de) * 1990-08-15 1997-07-10 Lilly Co Eli Ring-substituierte 2-Amino-1,2,3,4-tetra-hydronaphthaline, 3-Aminochromane und 3-Aminothiochromane
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto

Also Published As

Publication number Publication date
HU211848A9 (en) 1995-12-28
MY116454A (en) 2004-02-28
YU48927B (sh) 2002-12-10
DE69218813D1 (de) 1997-05-15
IL100858A (en) 1996-03-31
DE69218813T2 (de) 1997-08-14
EP0712837A2 (en) 1996-05-22
HU9500495D0 (en) 1995-04-28
ES2153071T3 (es) 2001-02-16
AU8168794A (en) 1995-02-23
HU9200396D0 (en) 1992-04-28
CZ288067B6 (cs) 2001-04-11
HUT62569A (en) 1993-05-28
RU2057751C1 (ru) 1996-04-10
RU94044322A (ru) 1996-10-10
CA2060815C (en) 2002-05-14
GR3035190T3 (en) 2001-04-30
EP0712837A3 (en) 1997-05-21
EP0498590A1 (en) 1992-08-12
CN1063870A (zh) 1992-08-26
JP3283892B2 (ja) 2002-05-20
NO920489L (no) 1992-08-10
YU12992A (sh) 1995-01-31
MX9200505A (es) 1992-08-01
IL100858A0 (en) 1992-11-15
CZ33292A3 (en) 1993-03-17
CA2060815A1 (en) 1992-08-09
IL114760A0 (en) 1995-11-27
US5426226A (en) 1995-06-20
ATE197145T1 (de) 2000-11-15
IE970857A1 (en) 2000-02-23
EP0498590B1 (en) 1997-04-09
ES2102456T3 (es) 1997-08-01
AU653197B2 (en) 1994-09-22
FI920526A0 (fi) 1992-02-07
ATE151419T1 (de) 1997-04-15
KR100219995B1 (ko) 1999-09-01
CN1140167A (zh) 1997-01-15
BR9200426A (pt) 1992-10-13
IL114760A (en) 1997-11-20
AU1077592A (en) 1992-08-13
RU2105756C1 (ru) 1998-02-27
DE69231538T2 (de) 2001-06-07
NZ264302A (en) 1995-04-27
AU664520B2 (en) 1995-11-16
HU225163B1 (en) 2006-07-28
FI920526A (fi) 1992-08-09
ZA92767B (en) 1993-08-03
CN1052218C (zh) 2000-05-10
IE920417A1 (en) 1992-08-12
HUT72659A (en) 1996-05-28
DK0712837T3 (da) 2000-11-20
EP0712837B1 (en) 2000-10-25
NO301825B1 (no) 1997-12-15
PT712837E (pt) 2001-03-30
CN1036392C (zh) 1997-11-12
DE69231538D1 (de) 2000-11-30
GR3023601T3 (en) 1997-08-29
US5571942A (en) 1996-11-05
HU221184B1 (en) 2002-08-28
NO920489D0 (no) 1992-02-06
DK0498590T3 (da) 1997-05-05
NZ241495A (en) 1994-10-26
JPH04327579A (ja) 1992-11-17

Similar Documents

Publication Publication Date Title
KR920016454A (ko) 환-치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만
NO940737D0 (no) Antidepressive midler
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
JP2002543183A5 (ko)
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
KR930701434A (ko) 옥사졸리딘 디온 유도체
DK0508687T3 (da) ATP-analoger
BR1100931A (pt) Compostos derivados de aril-heteroaril carbinóis, processos para a preparação dos compostos, composições farmacêuticas, e, uso dos compostos derivados de aril-heteroaril carbinóis
FI941644A0 (fi) Sieniä vastustavat triatsoliyhdisteet
ES2100211T3 (es) 2-amino-1,2,3,4-tetrahidronaftalenos, 3-aminocromanos y 3-aminotiocromanos sustituidos en el anillo.
RU92016545A (ru) Гетероциклические соединения, способ их получения и фармацевтическая композиция
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR910002873A (ko) 티아졸로[5,4-b] 아제핀 화합물
ES2065478T3 (es) 2-amino-1,2,3,4-tetrahidronaftalenos y 3-aminocromanos sustituidos en el anillo.
KR900014311A (ko) 치환 옥심 에테르 및 이것을 함유하는 살균제
ATE188217T1 (de) 1,2,3,4,10,14b-hexahydrodibenzo-c,f)pyrazino-1, - a)azepino-derivate
KR930009999A (ko) 부티르산 유도체 및 이를 함유하는 살충제 조성물
KR890002134A (ko) 1,2-벤즈 이속 사졸 및 1,2-벤즈 이소 티아졸 유도체
KR900009640A (ko) 벤족 사제핀 유도체
KR910000141A (ko) 이소옥사졸린-3-온 유도체의 항울제로서의 용도
TH32070A (th) อนุพันธ์ 5-ฟีนิล-3-(ไปเปอริดีน-4-อิล)-1,3,4-ออกซะไดอะซอล-2(3h) -โอน,การเตรียมและการใช้สารนี้ในการรักษา
CO5170504A1 (es) Compuestos de 1,2,3,4-tetrahidro-1-naftalenamina utiles en terapia
RU2006127045A (ru) Производные амидопиразола
KR940001889A (ko) 과민성 대장 증후군의 치료를 위한 이속사졸 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050418

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee